GenSight Biologics Announces the Filing of its 2022 Universa

Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for

Related Keywords

France , Paris , France General , French , James Palmer , Bernard Gilly , Gensight Biologics Euronext , Thomas Gidoin , Clothilde Caillet , Guillaume Van Renterghem , Jeanene Timberlake , Gensight Biologics , Corporate Communications , Regulatory News , Sight Biologics , Registration Document , Des March , Scientific Advice , Chief Executive Officer , Chief Financial Officer , Annual General Meeting , Sight Biologic , Mitochondrial Targeting Sequence , Leber Hereditary Optic Neuropathy , Gensight Biologic , Communications Director , Gefallene Big Techs , Gensight , Iologics , Nnounces , Filing , 022 , Niversal , Registration , Document , Reschedules , Nnual , Eneral , Meeting , Pune , 023 ,